Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-κB pathway

International Journal of Cancer

Volumn 125, Issue 6, 2009, Pages 1464-1472

  Takahashi Makise, Naoko ^a   Suzu, Shinya ^a   Hiyoshi, Masateru ^a   Ohsugi, Takeo ^a   Katano, Harutaka ^b   Umezawa, Kazuo ^c   Okada, Seiji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Animal model; Cepharanthine; NF B; Primary effusion lymphoma

Indexed keywords

CEPHARANTHINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZYLISOQUINOLINES; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, PRIMARY EFFUSION; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NF-KAPPA B; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68249154790     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24521     Document Type: Article

References (58)

1. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996;88:645-56.
2. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007;12:569-76.
3. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-91.
4. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-42.
5. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000;96:2537-42.
6. Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI, Bhatia KG. Inhibition of phosphatidylinositol 30-kinase/ AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005;11:3102-8.
7. Sun Q, Matta H, Chaudhary PM. The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-j B activation. Blood 2003;101: 1956-61.
8. Jarviluoma A, Ojala PM. Cell signaling pathways engaged by KSHV. Biochim Biophys Acta 2006;1766:140-58.
9. Jost PJ, Ruland J. Aberrant NF-jB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109: 2700-7.
10. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 2002;277:13745-51.
11. Keller SA, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, Schattner EJ, Cesarman E. NF-κB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006;107: 3295-302.
12. Furusawa S, Wu J. The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci 2007;80:1073-9.
13. Shiraishi N, Arima T, Aono K, Inouye B, Morimoto Y, Utsumi K. Inhibition by biscoclaurine alkaloid of lipid peroxidation in biological membranes. Physiol Chem Phys 1980;12:299-305.
14. Nagano M, Kanno T, Fujita H, Muranaka S, Fujiwara T, Utsumi K. Cepharanthine, an anti-inflammatory drug, suppresses mitochondrial membrane permeability transition. Physiol Chem Phys Med NMR 2003;35:131-43.
15. Kondo Y, Imai Y, Hojo H, Hashimoto Y, Nozoe S. Selective inhibition of T-cell-dependent immune responses by bisbenzylisoquinoline alkaloids in vivo. Int J Immunopharmacol 1992;14:1181-6.
16. Goto M, Zeller WP, Hurley RM. Cepharanthine (biscoclaurine alkaloid) treatment in endotoxic shock of suckling rats. J Pharm Pharmacol 1991;43:589-91.
17. Wu J, Suzuki H, Zhou YW, Liu W, Yoshihara M, Kato M, Akhand AA, Hayakawa A, Takeuchi K, Hossain K, Kurosawa M, Nakashima I. Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines. J Cell Biochem 2001;82:200-14.
18. Furusawa S, Wu J, Fujimura T, Nakano S, Nemoto S, Takayanagi M, Sasaki K, Takayanagi Y. Cepharanthine inhibits proliferation of cancer cells by inducing apoptosis. Methods Find Exp Clin Pharmacol 1998;20:87-97.
19. Harada K, Bando T, Yoshida H, Sato M. Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line. Oral Oncol 2001;37:643-51.
20. Kono K, Takahashi JA, Ueba T, Mori H, Hashimoto N, Fukumoto M. Effects of combination chemotherapy with biscoclaurine-derived alkaloid (Cepharanthine) and nimustine hydrochloride on malignant glioma cell lines. J Neurooncol 2002;56:101-8.
21. Biswas KK, Tancharoen S, Sarker KP, Kawahara K, Hashiguchi T, Maruyama I. Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1/2 and the downregulation of Akt. FEBS Lett 2006;580:703-10.
22. Okamoto M, Ono M, Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res Hum Retroviruses 1998;14: 1239-45.
23. Tamatani T, Azuma M, Motegi K, Takamaru N, Kawashima Y, Bando T. Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-κB activity in human oral squamous cell carcinoma cells. Int J Oncol 2007;31:761-8.
24. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 1996;2:342-6.
25. Katano H, Hoshino Y, Morishita Y, Nakamura T, Satoh H, Iwamoto A, Herndier B, Mori S. Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. J Med Virol 1999;58:394-401.
26. Miyagi J, Masuda M, Takasu N, Nagasaki A, Shinjyo T, Uezato H, Kakazu N, Tanaka Y. Establishment of a primary effusion lymphoma cell line (RM-P1) and in vivo growth system using SCID mice. Int J Hematol 2002;76:165-72.
27. Umezawa K, Ariga A, Matsumoto N. Naturally occurring and synthetic inhibitors of NF-jB functions. Anticancer Drug Des 2000;15: 239-44.
28. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
29. Komoriya A, Packard BZ, Brown MJ, Wu ML, Henkart PA. Assessment of caspase activities in intact apoptotic thymocytes using cellpermeable fluorogenic caspase substrates. J Exp Med 2000;191:1819-28.
30. Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, Watanabe T, Umezawa K, Urano T. In vivo antitumor activity of the NF-κB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005;26:1382-8.
31. Ohsugi T, Kumasaka T, Ishida A, Ishida T, Horie R, Watanabe T, Umezawa K, Yamaguchi K. In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line. HUT-102. Leuk Res 2006;30:90-7.
32. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, Miyake K, Nakauchi H, Shirasawa T, Saito T. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995;3: 771-82.
33. Okada S, Harada H, Ito T, Saito T, Suzu S. Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3(null) mice intrahepatic engrafted with cord bloodderived CD34 (1) cells. Int J Hematol 2008;88:476-82. 34. Katano H, Sato Y, Kurata T, Mori S, Sata T. High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. Am J Pathol 1999;155:47-52.
34. White IE, Campbell TB. Quantitation of cell-free and cell-associated Kaposi's sarcoma-associated herpesvirus DNA by real-time PCR. J Clin Microbiol 2000;38:1992-5.
35. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled. Annexin. V. J Immunol Methods 1995;184:39-51.
36. Okada S, Zhang H, Hatano M, Tokuhisa T. A physiologic role of Bcl-xL induced in activated macrophages. J Immunol 1998;160: 2590-6.
37. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004;199:993-1003.
38. Boshoff C, Gao SJ, Healy LE, Matthews S, Thomas AJ, Coignet L, Warnke RA, Strauchen JA, Matutes E, Kamel OW, Moore PS, Weiss RA, et al. Establishing a KSHV1 cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 1998;91:1671-9.
39. Uckun FM. Severe combined immunodeficient mouse models of human leukemia. Blood 1996;88:1135-46.
40. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, Leiter EH. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180-91.
41. Dick JE. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol 1996;8:197-206.
42. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007;7:118-30.
43. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007;25:1315-21.
44. Kawano N, Ishikawa F, Shimoda K, Yasukawa M, Nagafuji K, Miyamoto T, Baba E, Tanaka T, Yamasaki S, Gondo H, Otsuka T, Ohshima K, et al. Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/b2-microglobulin(null) mice. Leukemia 2005;19:1384-90.
45. Sun Q, Zachariah S, Chaudhary PM. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-jB activation. J Biol Chem 2003;278:52437-45.
46. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59.
47. Inoue J, Gohda J, Akiyama T, Semba K. NF-κB activation in development and progression of cancer. Cancer Sci 2007;98:268-74.
48. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13:738-47.
49. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci 2006;97:990-5.
50. Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Ashida Y, Hayashi Y, Sato M. Suppression of tumor necrosis factor α-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor κB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren's syndrome patients. Arthritis Rheum 2002;46:1585-94.
51. Oyaizu H, Adachi Y, Yasumizu R, Ono M, Ikebukuro K, Fukuhara S, Ikehara S. Protection of T cells from radiation-induced apoptosis by Cepharanthin. Int Immunopharmacol 2001;1:2091-9.
52. Halicka D, Ita M, Tanaka T, Kurose A, Darzynkiewicz Z. Biscoclaurine alkaloid cepharanthine protects DNA in TK6 lymphoblastoid cells from constitutive oxidative damage. Pharmacol Rep 2008;60:93-100.
53. Furuyama H, Koga Y, Hamasaki K, Kuroki F, Itami N, Ishikawa Y. Effective treatment of cyclic thrombocytopenia with cepharanthin. Pediatr Int 1999;41:584-5.
54. Saito N, Takemori N, Hirai K, Onodera R, Watanabe S, Kohgo Y. High-dose biscoclaurine alkaloids together with prednisolone raise platelet counts in chronic idiopathic thrombocytopenic purpura. Am J Hematol 1996;51:173-4.
55. Saito R, Tsuchiya S, Ishizuka T, Fueki N, Ezawa K, Minato K, Nakano H, Takise A, Kurihara M, Fueki R. Clinical effects of cepharanthin (Ceph.) on leukopenia by chemotherapy in lung cancer patients. Nippon Gan Chiryo Gakkai Shi 1989;24:2587-93.
56. Yasuda K, Moro M, Akasu M, Ohnishi A. Pharmacokinetic disposition of cepharanthine following single and multiple intravenous doses in healthy subjects. Jpn J Clin Pharmacol Ther 1989;20:741-9.
57. Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S, Kamizaki Y, Mitsuya H, Hata H. Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid. Int J Oncol 2008;33:807-14.
58. Harada K, Supriatno , Yamamoto S, Kawaguchi S, Yoshida H, Sato M. Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1. Anticancer Res 2003; 23:1441-8.